MENLO PARK, Calif., Feb. 3, 2011 /PRNewswire/ -- Corium International, Inc., a privately-held advanced transdermal drug delivery company, today announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the Board of Directors. Dr. Chaudhuri most recently served as President of Valeant Pharmaceuticals International and previously was President and Chief Executive Officer of Dow Pharmaceutical Services, Inc. Mr. Greenwood is Executive Vice President and Chief Financial Officer of Geron Corporation.
"We are excited and honored to welcome two executives of Bhaskar and David's caliber to Corium's Board of Directors," said Peter Staple, Corium's President and Chief Executive Officer. "They bring a breadth of experience and accomplishments that will be invaluable as Corium advances through its next stages of growth."With well over 20 years of industry management experience, Dr. Chaudhuri brings extensive product development and commercialization knowledge to Corium. Before joining Dow, he served as Vice President of R&D at Penederm, Inc., as General Manager of the Dermatology Division of Mylan Laboratories, and as Executive Vice President of Scientific Affairs at Bertek Pharmaceuticals, a subsidiary of Mylan, where he was responsible for research and development activities as well as certain of the company's manufacturing operations. As Chief Executive Officer of Dow, Dr. Chaudhuri led the company through a transition from a contract development focus to developing an attractive internal product pipeline and the company's eventual merger with Valeant. Dr. Chaudhuri holds a Doctorate in Physical Pharmacy, a Master's of Science in Industrial Pharmacy and a Bachelor's of Science in Pharmacy.
Mr. Greenwood brings substantial expertise in financing pharmaceutical and biotechnology companies. Before joining Geron, he held various positions in the investment banking field for over 15 years, includi